This Quantitative Pharmacology Assay (QPA) Core (C) supports the program entitled "Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy", submitted as an application responsive to RFA-HD-10-026: Specialized Center in Research in Pediatric Developmental Pharmacology (RPDP) Program (U54). The overall theme of the proposed program at UC San Diego is to bring together non-clinical and clinical experts in the fields of developmental physiology, pharmacology, and infectious diseases and conduct translational research to advance the field of pediatric developmental pharmacology. The QPA Core will provide timely, accurate and cost effective quantitative assays in support of the UC San Diego Research in Pediatric Development Pharmacology (RPDP) Center Projects and Pilot Projects. It will adopt published analytical methods and develop de-novo approaches to measure drugs, their metabolites and as antimicrobial peptides using small sample volumes appropriate for pediatric populations. These assay will cover various matrices including, plasma, intracellular, urine and tissue. Various methodologies are available including HPLC with UV detection, RIA, LC/MS/MS, and GC/MS. The QPA Core maintains medical licensure under CLIA and participates in NIAID's Clinical Pharmacology Quality Assurance program. The laboratory will work closely with the PM Core to determine assay sensitivity requirements so the most cost effective method can be used. The QPA Core will also collaborate with the Training &Outreach Core to provide assay methodology training opportunities for students, residents and fellows.
Development of sensitive, accurate and cost effective quantitative assays is an essential capability for clinical and translational pharmacology research. Use of small sample volumes and attention to metabolites and atypical matrices can maximize the knowledge generated from pediatric pharmacology studies.
|Sampson, Mario R; Frymoyer, Adam; Rattray, Benjamin et al. (2014) Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia. Ther Drug Monit 36:584-9|
|Tremoulet, Adriana; Le, Jennifer; Poindexter, Brenda et al. (2014) Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother 58:3013-20|
|Sinko, William; Wang, Yang; Zhu, Wei et al. (2014) Undecaprenyl diphosphate synthase inhibitors: antibacterial drug leads. J Med Chem 57:5693-701|
|Le, Jennifer; Ngu, Becky; Bradley, John S et al. (2014) Vancomycin monitoring in children using bayesian estimation. Ther Drug Monit 36:510-8|
|Gonzalez, David J; Vuong, Lisa; Gonzalez, Isaiah S et al. (2014) Phenol soluble modulin (PSM) variants of community-associated methicillin-resistant Staphylococcus aureus (MRSA) captured using mass spectrometry-based molecular networking. Mol Cell Proteomics 13:1262-72|
|Sakoulas, George; Rose, Warren; Nonejuie, Poochit et al. (2014) Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 58:1494-500|
|Autmizguine, Julie; Moran, Cassie; Gonzalez, Daniel et al. (2014) Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections. Pediatr Infect Dis J 33:e270-2|
|Sakoulas, George; Okumura, Cheryl Y; Thienphrapa, Wdee et al. (2014) Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) 92:139-49|
|Bayer, Arnold S; Mishra, Nagendra N; Sakoulas, George et al. (2014) Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 58:7462-7|
|Liu, Yan; Haste, Nina M; Thienphrapa, Wdee et al. (2014) Marinopyrrole derivatives as potential antibiotic agents against methicillin-resistant Staphylococcus aureus (III). Mar Drugs 12:2458-70|
Showing the most recent 10 out of 24 publications